Drug intelligence / Profile preview

RSV-NanoViaSkin

Development stage: Preclinical
Lead developer: Icosavax
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Transdermal

Overview

**RSV-NanoViaSkin** is an investigational epicutaneous pediatric vaccine designed for non-invasive delivery via the skin without the need for adjuvants. It targets respiratory syncytial virus (RSV) in infants and aims to become the world's first such vaccine using nano-patch technology for transcutaneous immunization. Developed with French government funding, it leverages skin immunization to induce protective immunity against RSV lower respiratory tract infections.[15]

Beyond the preview

Go deeper on RSV-NanoViaSkin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV-NanoViaSkin.

Explore the full profile